Groundbreaking research conducted by a collaborative team from Mount Sinai and Memorial Sloan Kettering Cancer Center has unveiled a novel mechanism by which monoamine neurotransmitters, specifically serotonin, dopamine, and histamine, regulate brain physiology and behavior. This research
In a groundbreaking partnership aimed at revolutionizing the production processes for stem cell-based therapies, Mytos has joined forces with Aspen Neuroscience to enhance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs). These cells are integral to Aspen’s ANPD001, an
Autoimmune diseases occur when the immune system erroneously targets the body's own cells and tissues. These diseases usually present a preclinical stage with mild symptoms or specific antibodies detectable in blood tests before the disease fully manifests. However, in some cases, these
Insilico Medicine, a clinical-stage company leveraging generative artificial intelligence (AI) for drug discovery and development, has announced promising results for its novel drug, ISM5411, aimed at treating Inflammatory Bowel Disease (IBD). This gut-restricted and PHD-specific inhibitor was
Glioblastoma, an aggressive and often fatal form of brain cancer, has long posed a formidable challenge to medical professionals. With an average lifespan of 12 to 15 months post-diagnosis and a mere 5% survival rate five years after diagnosis, the need for innovative treatments has never been more
Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new h
